(R**)- miniCHOP Therapy – 21 days

INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>*Reimbursement Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of Non Hodgkin Lymphoma in patients aged greater than 80 or with significant co-morbidities**</td>
<td>C85</td>
<td>00436a</td>
<td>Hospital</td>
</tr>
</tbody>
</table>

*If a reimbursement indicator is not defined, the indication has yet to be assessed through the formal HSE reimbursement process.

** RiTUXimab to be included in all CD20 positive patients

TREATMENT:

The starting dose of the drugs detailed above may be adjusted downward by the prescribing clinician, to consider each patient's individual clinical circumstances. Treatment is administered every 21 days for a maximum of 6 cycles or until disease progression or unacceptable toxicity develops.

Facilities to treat anaphylaxis MUST be present when therapy is administered.

<table>
<thead>
<tr>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Diluent &amp; Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>RitTUXimab (CD20+ patients only)</td>
<td>375mg/m²</td>
<td>IV infusion¹</td>
<td>500ml 0.9% sodium chloride at a maximum rate of 400mg/hr¹,3,4</td>
</tr>
<tr>
<td>1</td>
<td>Cyclophosphamide</td>
<td>400mg/m²</td>
<td>IV infusion²</td>
<td>250 mL 0.9% NaCl over 30minutes</td>
</tr>
<tr>
<td>1</td>
<td>DOXOrubicin</td>
<td>25mg/m²</td>
<td>IV Bolus over 15 mins</td>
<td>Into the side arm of a fast running 0.9% NaCl infusion</td>
</tr>
<tr>
<td>1</td>
<td>vinCRIStine</td>
<td>1mg</td>
<td>IV infusion</td>
<td>50ml minibag 0.9% NaCl over 15 minutes</td>
</tr>
<tr>
<td>1-5</td>
<td>Prednisolone</td>
<td>40mg/m² (**) PO</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹The recommended initial rate for infusion is 50 mg/hr; after the first 30 minutes, it can be escalated in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Subsequent infusions can be infused at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr.
Development of an allergic reaction may require a slower infusion rate. See Hypersensitivity/Infusion reactions under Adverse Effects/Regimen Specific Complications below.
Any deviation from the advised infusion rate should be noted in local policies

²Recommended Observation period: Patients should be observed for at least six hours after the start of the first infusion and for two hours after the start of the subsequent infusions for symptoms like fever and chills or other infusion-related symptoms. Any deviation should be noted in local policies.

³RiTUXimab should be diluted to a final concentration of 1-4mg/ml.

"Rapid rate infusion schedule"

If patients did not experience a serious infusion related reaction with their first or subsequent infusions of a dose of riTUXimab administered over the standard infusion schedule, a more rapid infusion can be administered for second and subsequent infusions using the same concentration as in previous infusions.
Initiate at a rate of 20% of the total dose for the first 30 minutes and then 80% of the dose for the next 60 minutes (total infusion time of 90 minutes). If the more rapid infusion is tolerated, this infusion schedule can be used when administering subsequent infusions.
Patients who have clinically significant cardiovascular disease, including arrhythmias, or previous serious infusion reactions to any prior biologic therapy or to riTUXimab, should not be administered the more rapid infusion.
**NCCP Chemotherapy Regimen**

---

**ELIGIBILITY:**
- Indications as above
- ECOG 0-2
- Patients over the age of 80 years, or with significant co-morbidities

**EXCLUSIONS:**
- Hypersensitivity to DOXOrubicin, cyclophosphamide, riTUXimab, vinCRIStine sulphate or any of the excipients.
- A cumulative life-long dose of 450mg/m² of DOXOrubicin should only be exceeded with extreme caution as there is as risk of irreversible congestive heart failure

**PRESCRIPTIVE AUTHORITY:**
The treatment plan must be initiated by a Consultant Medical Oncologist or Consultant Haematologist working in the area of haematological malignancies.

**TESTS:**

**Baseline tests:**
- Blood, renal and liver profile
- LDH, blood glucose, Uric Acid, SPEP.
- ECG
- MUGA or ECHO
- Virology screen -Hepatitis B (HBsAg, HBcoreAb) & C, HIV.
*See Adverse Effects/Regimen Specific Complications re Hepatitis B Reactivation

**Regular tests:**
- Blood, renal and liver profile prior to each cycle
- LDH prior to each cycle
- Evaluate for peripheral neuropathy prior to each cycle.
- MUGA or ECHO as clinically indicated

**Disease monitoring:**
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

---

*See Adverse Effects/Regimen Specific Complications re Hepatitis B Reactivation

---

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens
DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant
- No dose reductions of ritUXimab are recommended.

Haematological:

Table 1: Dose modification for haematological toxicity

<table>
<thead>
<tr>
<th>ANC (x 10^9/L)</th>
<th>Platelets (x 10^9/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1.0 and/or &lt;100</td>
<td>Consider treatment delay until count recovery to ANC ≥1.0 x 10^9/L and platelets ≥100 x 10^9/L with a max of 28 days between 2 consecutive cycles</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consider primary prophylaxis with G-CSF</td>
<td></td>
</tr>
</tbody>
</table>

Renal and Hepatic Impairment:

Table 2: Dose modifications based on renal and hepatic impairment

<table>
<thead>
<tr>
<th>Drug</th>
<th>Renal impairment</th>
<th>Hepatic impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>ritUXimab</td>
<td>No dose adjustment necessary</td>
<td>No dose adjustment necessary</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>GFR (ml/min)</td>
<td>Dose</td>
</tr>
<tr>
<td>&gt;20</td>
<td>100%</td>
<td>Total Bilirubin (micromol/L)</td>
</tr>
<tr>
<td>10-20</td>
<td>75%</td>
<td>&gt;20-51</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50%</td>
<td>&gt;51-85</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;85</td>
</tr>
<tr>
<td>DOXOrubicin</td>
<td>Dose reduce in severe renal impairment</td>
<td>If AST 2-3 x normal, give 75% dose.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If AST &gt;3 x ULN, give 50% dose</td>
</tr>
<tr>
<td>VinCRIStine</td>
<td>No dose reduction required</td>
<td>Bilirubin (micromol/L)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;26-51</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;51</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;51</td>
</tr>
</tbody>
</table>

Neurotoxicity:

Table 3: Dose modification of vinCRIStine based on neurotoxicity (CTCAE v4.0)

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Dose of VinCRIStine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>100%</td>
</tr>
<tr>
<td>Grade 2</td>
<td>Discuss reducing or withholding vinCRIStine with Consultant</td>
</tr>
</tbody>
</table>
**NCCP Chemotherapy Regimen**

Table 4: Dose modification schedule of riTUXimab based on adverse events

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Discontinue</th>
<th>Recommended dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe infusion related reaction (e.g. dyspnoea, bronchospasm, hypotension or hypoxia) First occurrence</td>
<td>Interrupt infusion immediately. Evaluate for cytokine release/tumour lysis syndrome (appropriate laboratory tests) and pulmonary infiltration (chest x-ray). Infusion may be restarted on resolution of all symptoms, normalisation of laboratory values and chest x-ray findings at no more than one-half the previous rate. Consider coverage with steroids for those who are not already receiving steroids.</td>
<td></td>
</tr>
<tr>
<td>Second occurrence</td>
<td>Consider discontinuing treatment</td>
<td></td>
</tr>
<tr>
<td>Mild or moderate infusion-related reaction</td>
<td>Reduce rate of infusion. The infusion rate may be increased upon improvement of symptoms</td>
<td></td>
</tr>
</tbody>
</table>

**SUPPORTIVE CARE:**

**EMETOGENIC POTENTIAL:** High (Refer to local policy).

**PREMEDICATIONS:**
- Premedication consisting of an anti-pyretic and an anti-histamine should always be administered before each infusion of riTUXimab.

Table 5: Suggested pre-medications prior to riTUXimab infusion:

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Dose</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paracetamol</td>
<td>1g</td>
<td>PO 60 minutes prior to riTUXimab infusion</td>
</tr>
<tr>
<td>Chlorphenamine</td>
<td>10mg</td>
<td>IV bolus 60 minutes prior to riTUXimab infusion</td>
</tr>
</tbody>
</table>

**OTHER SUPPORTIVE CARE:**
- Tumour lysis syndrome prophylaxis (Refer to local policy)
- Proton pump Inhibitor (Refer to local policy)
- Consider PJP prophylaxis (Refer to local policy)
- Anti-viral prophylaxis (Refer to local policy)
- Anti-fungal prophylaxis (Avoid the concurrent use of azoles and vinCRISTine) (Refer to local policy)
- Prophylactic regimen against vinCRISTine induced constipation is recommended (Refer to local policy).
- G-CSF prophylaxis may be required, please discuss with consultant
ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Hypersensitivity/Infusion Reactions:** Close monitoring is required throughout the first infusion of RiTUXimab. (Refer to local policy). RiTUXimab can cause allergic type reactions during the IV infusion such as hypotension, wheezing, rash, flushing, pruritis, sneezing, cough, fever or faintness.

- **Cardiac Disorders:** Patients with a history of cardiac disease and/or cardiotoxic chemotherapy should be monitored closely while on RiTUXimab. DOXOrubicin is cardiotoxic and must be used with caution, if at all, in patients with cardiac dysfunction.

- **Neuropathy:** VinCRIStine may cause peripheral neuropathy which is dose related and cumulative, requiring monitoring before each dose is administered. The presence of pre-existing neuropathies or previous treatment with other neurotoxic drugs may increase risk of peripheral neuropathy. Patients with mild peripheral neuropathy can usually continue to receive full doses of vinCRIStine, but when symptoms increase in severity and interfere with neurologic function, dose reduction or discontinuation of the drug may be necessary. The natural history following discontinuation of treatment is gradual improvement, which may take up to several months. A routine prophylactic regimen against constipation is recommended for all patients receiving vinCRIStine sulphate. Paralytic ileus may occur. The ileus will reverse itself upon temporary discontinuance of vinCRIStine and with symptomatic care.

- **Extravasation:** DOXOrubicin and vinCRIStine cause pain and possible tissue necrosis if extravasated. (Refer to local policy).

- **Severe Cytokine Release syndrome:** Usually occurs within 1 to 2 hours of initiating the first infusion. This syndrome may be associated with some features of cytokine release/tumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphatemia, acute renal failure, elevated lactate dehydrogenase (LDH) and may be associated with acute respiratory failure and death. Pulmonary interstitial infiltrates or oedema visible on chest x-ray may accompany acute respiratory failure. For severe reactions, stop the infusion immediately and evaluate for tumour lysis syndrome and pulmonary infiltration. Aggressive symptomatic treatment is required. The infusion can be resumed at no more than one-half the previous rate once all symptoms have resolved, and laboratory values and chest x-ray findings have normalized.

- **Hepatitis B Reactivation:** All lymphoma patients should be tested for both HBsAg and HBcoreAb as per local policy. If either test is positive, such patients should be treated with lamivudine 100 mg/day orally, for the entire duration of chemotherapy and for six months afterwards. Such patients should also be monitored with frequent liver function tests and hepatitis B virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to stopping chemotherapy.

Please Refer to NCCP Protocol 00208 RiTUXimab Monotherapy for more detailed information on adverse reactions/Regimen Specific Complications associated with RiTUXimab Therapy.
NCCP Chemotherapy Regimen

DRUG INTERACTIONS:
- Antihypertensives: Additive effect of hypotension during riTUXimab infusion. Consider withholding antihypertensives 12 hours before and during riTUXimab infusion.
- DOXOrubicin cardiotoxicity is enhanced by previous or concurrent use of other anthracyclines, or other potentially cardiotoxic drugs (e.g. 5-FU, cyclophosphamide or paclitaxel) or with products affecting cardiac function (e.g. calcium antagonists).
- Current drug interaction databases should be consulted for more information including potential for interactions with CYP3A4 inhibitors/inducers

ATC CODE:
- RiTUXimab L01XC02
- Cyclophosphamide L01AA01
- DOXOrubicin L01DB01
- VinCRIStine L01CA02

REFERENCES:

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Amendment</th>
<th>Approved By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>05/11/2018</td>
<td></td>
<td>Dr Ezzat Elhassadi, Prof Maccon Keane</td>
</tr>
</tbody>
</table>
NCCP Chemotherapy Regimen

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

1 ODMS – Oncology Drug Management System
CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes
Further details on the Cancer Drug Management Programme is available at; http://www.hse.ie/eng/services/list/5/cancer/profinomedonc/cdmp/

ii The rapid infusion is an unlicensed means of administration of riTUXimab for the indications described above, in Ireland. Patient’s should be informed of this and consented to treatment in line with the hospital’s policy on the use of unlicensed medication and unlicensed or “off label” indications. Prescribers should be fully aware of their responsibility in communicating any relevant information to the patient and also ensuring that the unlicensed or “off label” means of administration has been acknowledged by the hospital’s Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.

Cardiotoxicity is a risk associated with anthracycline therapy that may be manifested by early (acute) or late (delayed) effects.

Risk factors for developing anthracycline-induced cardiotoxicity include:
• high cumulative dose, previous therapy with other anthracyclines or anthracyclines
• prior or concomitant radiotherapy to the mediastinal/pericardial area
• pre-existing heart disease
• concomitant use of other potentially cardiotoxic drugs

In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors above and to the age of the patient.